Protein farnesyl transferase as a target for the development of anticancer drugs

Research output: Contribution to journalReview article

21 Citations (Scopus)

Abstract

Protein farnesylation (addition of 15-carbon isoprene units), catalyzed by protein farnesyl transferase (FT), permits the anchoring of a number of cellular proteins to cell membranes, where they mediate their effects. Because farnesylated proteins including Ras, Rac, Rho and other small G-proteins are involved in cell transformation and proliferation, protein farnesyl transferase inhibitors (FTIs) have emerged as a novel class of antineoplastic agents. Four FTIs are currently in clinical trials, with two of them in phase II testing. Preliminary evidence of clinical activity has been documented in a number of tumor types including non-small cell lung cancer, breast cancer and leukemia. While the FTIs clearly inhibit FT, their mechanism of cytotoxicity is unclear. Also, because the cellular target of FTIs is known, there is considerable interest in developing markers of FT inhibition in patient tissues.

Original languageEnglish (US)
Pages (from-to)1069-1079
Number of pages11
JournalDrugs of the Future
Volume25
Issue number10
DOIs
StatePublished - Jan 1 2000

Fingerprint

Transferases
Pharmaceutical Preparations
Proteins
Protein Prenylation
Breast Neoplasms
ras Proteins
Monomeric GTP-Binding Proteins
Non-Small Cell Lung Carcinoma
Antineoplastic Agents
Membrane Proteins
Leukemia
Carbon
Cell Proliferation
Clinical Trials
Neoplasms

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

Protein farnesyl transferase as a target for the development of anticancer drugs. / Adjei, Alex.

In: Drugs of the Future, Vol. 25, No. 10, 01.01.2000, p. 1069-1079.

Research output: Contribution to journalReview article

@article{18bd32d2ec84440eb79cc491b0b6bb39,
title = "Protein farnesyl transferase as a target for the development of anticancer drugs",
abstract = "Protein farnesylation (addition of 15-carbon isoprene units), catalyzed by protein farnesyl transferase (FT), permits the anchoring of a number of cellular proteins to cell membranes, where they mediate their effects. Because farnesylated proteins including Ras, Rac, Rho and other small G-proteins are involved in cell transformation and proliferation, protein farnesyl transferase inhibitors (FTIs) have emerged as a novel class of antineoplastic agents. Four FTIs are currently in clinical trials, with two of them in phase II testing. Preliminary evidence of clinical activity has been documented in a number of tumor types including non-small cell lung cancer, breast cancer and leukemia. While the FTIs clearly inhibit FT, their mechanism of cytotoxicity is unclear. Also, because the cellular target of FTIs is known, there is considerable interest in developing markers of FT inhibition in patient tissues.",
author = "Alex Adjei",
year = "2000",
month = "1",
day = "1",
doi = "10.1358/dof.2000.025.10.659165",
language = "English (US)",
volume = "25",
pages = "1069--1079",
journal = "Drugs of the Future",
issn = "0377-8282",
publisher = "Prous Science",
number = "10",

}

TY - JOUR

T1 - Protein farnesyl transferase as a target for the development of anticancer drugs

AU - Adjei, Alex

PY - 2000/1/1

Y1 - 2000/1/1

N2 - Protein farnesylation (addition of 15-carbon isoprene units), catalyzed by protein farnesyl transferase (FT), permits the anchoring of a number of cellular proteins to cell membranes, where they mediate their effects. Because farnesylated proteins including Ras, Rac, Rho and other small G-proteins are involved in cell transformation and proliferation, protein farnesyl transferase inhibitors (FTIs) have emerged as a novel class of antineoplastic agents. Four FTIs are currently in clinical trials, with two of them in phase II testing. Preliminary evidence of clinical activity has been documented in a number of tumor types including non-small cell lung cancer, breast cancer and leukemia. While the FTIs clearly inhibit FT, their mechanism of cytotoxicity is unclear. Also, because the cellular target of FTIs is known, there is considerable interest in developing markers of FT inhibition in patient tissues.

AB - Protein farnesylation (addition of 15-carbon isoprene units), catalyzed by protein farnesyl transferase (FT), permits the anchoring of a number of cellular proteins to cell membranes, where they mediate their effects. Because farnesylated proteins including Ras, Rac, Rho and other small G-proteins are involved in cell transformation and proliferation, protein farnesyl transferase inhibitors (FTIs) have emerged as a novel class of antineoplastic agents. Four FTIs are currently in clinical trials, with two of them in phase II testing. Preliminary evidence of clinical activity has been documented in a number of tumor types including non-small cell lung cancer, breast cancer and leukemia. While the FTIs clearly inhibit FT, their mechanism of cytotoxicity is unclear. Also, because the cellular target of FTIs is known, there is considerable interest in developing markers of FT inhibition in patient tissues.

UR - http://www.scopus.com/inward/record.url?scp=0033637047&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033637047&partnerID=8YFLogxK

U2 - 10.1358/dof.2000.025.10.659165

DO - 10.1358/dof.2000.025.10.659165

M3 - Review article

AN - SCOPUS:0033637047

VL - 25

SP - 1069

EP - 1079

JO - Drugs of the Future

JF - Drugs of the Future

SN - 0377-8282

IS - 10

ER -